Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Beam Therapeutics Inc (BEAM)

Beam Therapeutics Inc (BEAM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,839,270
  • Shares Outstanding, K 101,475
  • Annual Sales, $ 63,520 K
  • Annual Income, $ -376,740 K
  • EBIT $ -466 M
  • EBITDA $ -467 M
  • 60-Month Beta 2.21
  • Price/Sales 44.96
  • Price/Cash Flow N/A
  • Price/Book 2.96

Options Overview Details

View History
  • Implied Volatility 97.84% (+25.83%)
  • Historical Volatility 65.85%
  • IV Percentile 92%
  • IV Rank 67.98%
  • IV High 119.34% on 05/06/25
  • IV Low 52.20% on 08/06/25
  • Expected Move (DTE 20) 3.49 (12.46%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 2,120
  • Volume Avg (30-Day) 665
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 28,586
  • Open Int (30-Day) 38,038
  • Expected Range 24.50 to 31.47

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.13
  • Number of Estimates 5
  • High Estimate -0.90
  • Low Estimate -1.24
  • Prior Year -1.09
  • Growth Rate Est. (year over year) -3.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.30 +20.09%
on 12/03/25
29.16 -4.03%
on 12/04/25
+2.95 (+11.79%)
since 11/26/25
3-Month
20.23 +38.31%
on 11/20/25
31.54 -11.29%
on 10/21/25
+5.01 (+21.81%)
since 09/26/25
52-Week
13.52 +106.88%
on 04/07/25
35.25 -20.62%
on 02/18/25
-0.72 (-2.51%)
since 12/26/24

Most Recent Stories

More News
Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...

BEAM : 27.98 (-0.57%)
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting

Updated Data from 31 Adult and Adolescent SCD Patients  Treated with risto-cel (Formerly BEAM-101) Show Mean He moglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to

BEAM : 27.98 (-0.57%)
Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference

CAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...

BEAM : 27.98 (-0.57%)
2 Stocks to Buy Now to Profit from the Rise of Robotics

Investors betting on the future of automation in high-tech manufacturing would do well to keep these two stocks on their radar.

BEAM : 27.98 (-0.57%)
LCID : 11.41 (-3.39%)
ROK : 399.79 (+0.39%)
BA : 216.44 (-0.79%)
Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

Expanded Dose Exploration in Part A and Dose Escalation in Part B of BEAM-302 Phase 1/2 Study in Alpha-1 Antitrypsin Deficiency Ongoing; Updated Data and Clinical Development Update Expected in Early 2026...

BEAM : 27.98 (-0.57%)
Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...

BEAM : 27.98 (-0.57%)
H.C. Wainwright Reaffirms Their Buy Rating on Beam Therapeutics (BEAM)

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Beam Therapeutics today and set a price target of $80.00. The company’s shares closed yesterday at $27.87.Elevate Your Investing Strategy:...

BEAM : 27.98 (-0.57%)
Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences

CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...

BEAM : 27.98 (-0.57%)
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...

BEAM : 27.98 (-0.57%)
BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark

Beam Therapeutics BEAM incurred a loss of $1.00 per share in the second quarter of 2025, which was narrower than the Zacks Consensus Estimate of a loss of $1.04. The company had reported a loss of $1.11...

BEAM : 27.98 (-0.57%)
IMCR : 36.13 (-1.20%)
ARVN : 12.16 (-0.08%)
CRMD : 12.53 (+2.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Beam Therapeutics Inc. is a biotechnology company. It engages in developing precision genetic medicines through base editing. Beam Therapeutics Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 29.76
2nd Resistance Point 28.89
1st Resistance Point 28.44
Last Price 27.98
1st Support Level 27.12
2nd Support Level 26.25
3rd Support Level 25.80

See More

52-Week High 35.25
Last Price 27.98
Fibonacci 61.8% 26.95
Fibonacci 50% 24.39
Fibonacci 38.2% 21.82
52-Week Low 13.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar